Reserve drug product samples are not appropriately identified, representative of each lot or batch of drug product and retained and stored under conditions consistent with product labeling.
See every finding in this document View official sourceBy Category
US FDA Labeling and packaging findings
by this agency in this category 441 findings drawn from 397 published documents. The most recent cases are below; the full set is in search.
See all US FDA Labeling and packaging findingsCompanies with the most findings
Recent findings
You did not establish packaging specifications.
See every finding in this document View official sourceStrict control is not exercised over labeling issued for use in drug product labeling operations.
See every finding in this document View official sourceYou did not establish specifications to ensure that you applied the specified label.
See every finding in this document View official sourceReserve drug product samples are not representative of each lot or batch of drug product and retained and stored under conditions consistent with product labeling.
See every finding in this document View official sourceA drug is misbranded under section 502(f)(1) of the FD&C Act if its labeling fails to bear adequate directions for use. "Adequate directions for use" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the…
View official sourceOther agencies
These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-09-04, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
